ADJUVANT POST-SURGERY TREATMENT OF RECURRENT IDH2 MUTANT ANAPLASTIC OLIGODENTROGLIOMA (AO) WITH IDH2 INHIBITOR, ENASIDENIB: A CASE REPORT

被引：0
|
作者：
Kong, Xiao-Tang [1 ]
Fu, Beverly Dan [1 ]
Myung, Joon [1 ]
Bota, Daniela [2 ]
机构：
[1] UC Irvine, Orange, CA USA
[2] Univ Calif Irvine, Irvine, CA USA
来源：
NEURO-ONCOLOGY | 2023年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
INNV-07
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The role of enasidenib in the treatment of mutant IDH2 acute myeloid leukemia
    Abou Dalle, Iman
    DiNardo, Courtney D.
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (07) : 163 - 173
  • [2] Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
    Dogra, Raghav
    Bhatia, Rohit
    Shankar, Ravi
    Bansal, Parveen
    Rawal, Ravindra K.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 18 (14) : 1936 - 1951
  • [3] Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
    DiNardo, Courtney D.
    Venugopal, Sangeetha
    Lachowiez, Curtis
    Takahashi, Koichi
    Loghavi, Sanam
    Montalban-Bravo, Guillermo
    Wang, Xuemei
    Carraway, Hetty
    Sekeres, Mikkael
    Sukkur, Ameenah
    Hammond, Danielle
    Chien, Kelly
    Maiti, Abhishek
    Masarova, Lucia
    Sasaki, Koji
    Alvarado, Yesid
    Kadia, Tapan
    Short, Nicholas J.
    Daver, Naval
    Borthakur, Gautam
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Patel, Bhumika
    Dezern, Amy
    Roboz, Gail
    Garcia-Manero, Guillermo
    BLOOD ADVANCES, 2023, 7 (11) : 2378 - 2387
  • [4] Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
    Stein, Eytan M.
    DiNardo, Courtney D.
    Pollyea, Daniel A.
    Fathi, Amir T.
    Roboz, Gail J.
    Altman, Jessica K.
    Stone, Richard M.
    DeAngelo, Daniel J.
    Levine, Ross L.
    Flinn, Ian W.
    Kantarjian, Hagop M.
    Collins, Robert
    Patel, Manish R.
    Frankel, Arthur E.
    Stein, Anthony
    Sekeres, Mikkael A.
    Swords, Ronan T.
    Medeiros, Bruno C.
    Willekens, Christophe
    Vyas, Paresh
    Tosolini, Alessandra
    Xu, Qiang
    Knight, Robert D.
    Yen, Katharine E.
    Agresta, Sam
    de Botton, Stephane
    Tallman, Martin S.
    BLOOD, 2017, 130 (06) : 722 - 731
  • [5] Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia
    Stein, Eytan M.
    FUTURE ONCOLOGY, 2018, 14 (01) : 23 - 40
  • [6] A personalized medicine approach identifies enasidenib as an efficient treatment for IDH2 mutant chondrosarcoma
    Rey, Veronica
    Tornin, Juan
    Alba-Linares, Juan Jose
    Robledo, Cristina
    Murillo, Dzohara
    Rodriguez, Aida
    Gallego, Borja
    Huergo, Carmen
    Viera, Cristina
    Brana, Alejandro
    Astudillo, Aurora
    Heymann, Dominique
    Szuhai, Karoly
    Bovee, Judith V. M. G.
    Fernandez, Agustin F.
    Fraga, Mario F.
    Alonso, Javier
    Rodriguez, Rene
    EBIOMEDICINE, 2024, 102
  • [7] Discovery of mutant IDH2 inhibitors for the treatment of cancer
    Travins, Jeremy M.
    Popovici-Muller, Janeta
    DeLaBarre, Byron
    Gross, Stefan
    Yang, Hua
    Wang, Fang
    Yen, Katherine E.
    Salituro, Francesco G.
    Saunders, Jeffrey O.
    Dang, Lenny
    Biller, Scott A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
  • [8] Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
    Quek, Lynn
    David, Muriel D.
    Kennedy, Alison
    Metzner, Marlen
    Amatangelo, Michael
    Shih, Alan
    Stoilova, Bilyana
    Quivoron, Cyril
    Heiblig, Mael
    Willekens, Christophe
    Saada, Veronique
    Alsafadi, Samar
    Vijayabaskar, M. S.
    Peniket, Andy
    Bernard, Oliver A.
    Agresta, Sam
    Yen, Katharine
    MacBeth, Kyle
    Stein, Eytan
    Vassiliou, George S.
    Levine, Ross
    De Botton, Stephane
    Thakurte, Anjan
    Penard-Lacronique, Virginie
    Vyas, Paresh
    NATURE MEDICINE, 2018, 24 (08) : 1167 - +
  • [9] Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
    Lynn Quek
    Muriel D. David
    Alison Kennedy
    Marlen Metzner
    Michael Amatangelo
    Alan Shih
    Bilyana Stoilova
    Cyril Quivoron
    Maël Heiblig
    Christophe Willekens
    Véronique Saada
    Samar Alsafadi
    M. S. Vijayabaskar
    Andy Peniket
    Oliver A. Bernard
    Sam Agresta
    Katharine Yen
    Kyle MacBeth
    Eytan Stein
    George S. Vassiliou
    Ross Levine
    Stephane De Botton
    Anjan Thakurta
    Virginie Penard-Lacronique
    Paresh Vyas
    Nature Medicine, 2018, 24 : 1167 - 1177
  • [10] Differentiation Syndrome in a Patient With NSCLC Harboring IDH2 Mutation Treated With Enasidenib: Case Report
    Sukhadia, Bhoomika
    Tan, Dean
    Oh, Youjin
    Shah, Zunairah
    Chae, Young Kwang
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (10):
12345